2023 World Conference on Lung Cancer (Posters)-EP12.03. Previously Treated Advanced-Disease NSCLC KRAS G12C From a Canadian Multi-Institutional Real-World Evidence Database (CARMA)

EP12.03. Previously Treated Advanced-Disease NSCLC KRAS G12C From a Canadian Multi-Institutional Real-World Evidence Database (CARMA) - PDF(Slides)

Back to course

Pdf Summary

A real-world evidence study conducted across multiple Canadian institutions aimed to understand the treatment patterns and outcomes of previously treated patients with KRASG12C-mutated non-small cell lung cancer (NSCLC). The current standard of care for these patients is immune-checkpoint inhibitors (ICI) chemotherapy. However, with the emergence of targeted therapies such as sotorasib and others, there is a need to identify the real-world population that would be eligible for these treatments post-ICI.<br /><br />The study captured data on treatment patterns and outcomes of patients with KRASG12C-mutated tumors from eight Canadian centers. Overall survival (OS) and real-world progression-free survival (rwPFS) were evaluated using multivariate Cox proportional hazards models. The study also estimated the prevalence of KRAS mutations in advanced-stage NSCLC across representative sites in Canada.<br /><br />The study included patients who were diagnosed with advanced-stage NSCLC between 2015 and 2021, had molecular testing confirming a KRASG12C mutation, and were previously treated with ICI before initiating a subsequent line of therapy. Among the patients included in the analysis cohort, only 50% received a subsequent line of systemic therapy.<br /><br />The treatment patterns post-ICI varied, with 37% receiving doublet chemotherapy, 27% receiving single-agent chemotherapy, 22% receiving targeted therapy, 14% receiving ICI with or without chemotherapy, and 1% receiving unknown trial therapy.<br /><br />The median overall survival for patients excluding those who received sotorasib was 12.6 months, and the real-world progression-free survival was 4.1 months. Targeted therapy was associated with a significantly better rwPFS compared to doublet chemotherapy regimens.<br /><br />The study highlighted that 50% of patients with KRASG12C-mutated tumors did not receive treatment post-ICI, mainly due to poor performance status and lack of treatment options. The overall survival and rwPFS in Canadian patients with KRASG12C-mutated advanced NSCLC were relatively poor. The study suggests that patient outcomes could potentially be improved with increased availability of KRASG12C inhibitors at earlier lines of therapy.<br /><br />The study was funded by Amgen Canada and conducted under the leadership of Dr. Stephanie Snow and Dr. Geoffrey Liu.

Asset Subtitle

Luna Zhan

Meta Tag

Speaker Luna Zhan

Topic Metastatic NSCLC: Targeted Therapy - Other

Keywords

real-world evidence study

KRASG12C-mutated non-small cell lung cancer

treatment patterns

outcomes

immune-checkpoint inhibitors

sotorasib

targeted therapies

prevalence of KRAS mutations

advanced-stage NSCLC

systemic therapy